Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson
CEO, Wayne Paterson
Source: Anteris Technologies
Market Herald logo


Be the first with the news that moves the market
  • Anteris Technologies (AVR) has expanded its funding package with Mercer Street Global Opportunity Fund
  • The health technology stock has closed the second tranche of funding facility with Mercer, raising $1 million before costs
  • The company has also announced a $3.05 million capital raise via the issue of shares and convertible notes to Mercer
  • The notes have a face value of $2.7 million, while over 55,000 shares prices at $9.58 will be issued and an additional 350,000 options
  • The extra funding from Mercer will help Anteris advance the development of DurAVR — a 3D single-piece aortic valve for the treatment of aortic stenosis
  • Shares in Anteris Technologies are down 1.09 per cent at $10.00 per share

Anteris Technologies (AVR) has expanded its funding package with Mercer Street Global Opportunity Fund.

The health technology stock advises it’s closed the second tranche of its funding facility with Mercer, announced back in January.

$1.08 million in convertible notes have been issued, helping raise an extra $1 million before costs for AVR.

The company has also unveiled a new $3.05 million funding package via the issue of shares, options and convertible notes to Mercer.

The notes have a face value of $2.7 million and will raise an additional $2.5 million in capital for Anteris.

The company will also issue over 55,000 shares at $9.58 per share — a 10 per cent discount to the five-day volume-weighted average price of AVR shares up to April 8.

Issuing the shares will reduce the total amount available to drawn down to $15.95 million, while a cash fee of 1.5 per cent is also payable.

Additionally, the healthtech stock will offer 350,000 three-year options to Mercer to purchase new shares in the company at an exercise price of $10.00.

Explaining what the additional funding will be used for, Anteris stated it would help advance the development of DurAVR, the company’s 3D single-piece aortic valve which can be used in the treatment of aortic stenosis.

Company shares are trading 1.09 per cent in the red at $10.00 per share at the close of market on Monday.

AVR by the numbers
More From The Market Herald
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) seeks to expand to Greece

Little Green Pharma (ASX:LGP) seeks to expand to Greece

" HeraMED (ASX:HMD) signs “significant milestone” with a Perth hospital

Digital maternity care company HeraMED (ASX:HMD) has hit a "truly significant milestone" with a Perth hospital,…

" ResApp Health (ASX:RAP) signs LOI to launch diagnostic app in the Philippines

ResApp Health (ASX:RAP) smartphone diagnostic test is set to launch in the Philippines through an agreement…

" Emyria (ASX:EMD) set to begin ultra-pure CBD trial

Emyria (ASX:EMD) is set to begin phase one clinical trials of its ultra-pure CBD drug candidate,…